KẾT QUẢ ĐIỀU TRỊ BỆNH NHÂN UNG THƯ BUỒNG TRỨNG GIAI ĐOẠN IIIC – IV BẰNG PHÁC ĐỒ PHỐI HỢP PHẪU THUẬT, HÓA CHẤT TIỀN PHẪU, HÓA CHẤT HẬU PHẪU TẠI BỆNH VIỆN K

Abstract

Materials and methods: Prospective combined retrospective descriptip study 58 patients diagnosed with stage IIIC-IV ovarian cancer who received surgical combined preoperative chemotherapy and postoperative chemotherapy at K hospital from 9/2019-10/2023. Results: Overall survival time for the entire study patient population was 34 months (CI 95% 29.3-38.7 months). In which, the survival time of the entire group receiving chemotherapy was 32 months, the survival time of the bevacizumab combination chemotherapy group was 31 months (p = 0.65). The median overall survival time for stage IIIC patients is 31 months, and for stage IV patients is 30 months. There has been no patient death during the follow-up period of pCR. Conclusions: Surgical combined preoperative chemotherapy and postoperative chemotherapy brings good results in treating patients with stage IIIC and IV ovarian cancer.